BioNTech to Unveil First Data for Novel-Novel Lung Cancer Combo at WCLC 2026
BNTX sits 39% above its 52-week low of $79.52 on elevated volume (8.2× avg).
Summary
BioNTech will present first global data for its pumitamig + elfetabart drozuntecan combination in advanced lung cancer at WCLC 2026 in Seoul, September 12-15. This is the first clinical evidence for any PD-(L)1xVEGF bispecific combined with an ADC in lung cancer, a key differentiator for the company's novel-novel strategy. Updated overall survival data from the PRESERVE-003 Phase 3 trial of gotistobart in squamous NSCLC will also be presented, adding to the evidence base for this chemotherapy-free approach. The announcement follows recent positive interim Phase 2 data for pumitamig and a leadership transition to new CEO Guido Oelkers. Traders will watch the September 15 oral presentation for efficacy and safety signals that could validate the combination backbone strategy.
At the time of this announcement, BNTX was trading at $110.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.